1. Home >
  2. M&A >
  3. Divestiture >
  4. United States >
  5. Maryland >
  6. SERB Pharmaceuticals Acquires Wellstat Therapeutics - Vistogard and Xuriden

M&A Deal Summary

SERB Pharmaceuticals Acquires Wellstat Therapeutics - Vistogard and Xuriden

On July 13, 2023, SERB Pharmaceuticals acquired life science company Wellstat Therapeutics - Vistogard and Xuriden from Wellstat Therapeutics

Acquisition Highlights
  • This is SERB Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is SERB Pharmaceuticals’ 2nd transaction in the United States.
  • This is SERB Pharmaceuticals’ 1st transaction in Maryland.

M&A Deal Summary
Date 2023-07-13
Target Wellstat Therapeutics - Vistogard and Xuriden
Sector Life Science
Buyer(s) SERB Pharmaceuticals
Sellers(s) Wellstat Therapeutics
Deal Type Divestiture

Target

Wellstat Therapeutics - Vistogard and Xuriden

Rockville, Maryland, United States
Wellstat Therapeutics's Vistogard and Xuriden provides emergency treatment for adult and pediatric patients with hereditary orotic aciduria (HOA)[ii], an ultra-rare, orphan genetic disorder associated megaloblastic anemia as well as failure to thrive, developmental delay, epilepsy, susceptibility to infection, and orotic acid crystals in the urine.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

SERB Pharmaceuticals

Luxembourg, Luxembourg
Category Company
Founded 1951
Sector Life Science
Employees390
DESCRIPTION

SERB Pharmaceuticals is an independent niche specialty pharma company focused on niche branded prescription medicines. The company has a strong focus on therapeutic areas such as critical and emergency care, neurology, diagnostics and endocrinology. SERB Pharmaceuticals was founded in 1951 and is based in Luxembourg.

DEAL STATS #
Overall 2 of 3
Sector: Life Science M&A 1 of 2
Type: Divestiture M&A Deals 2 of 2
State: Maryland M&A 1 of 1
Country: United States M&A 2 of 3
Year: 2023 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-12-01 BTG Specialty Pharmaceuticals

Gladwyne, Pennsylvania, United States

BTG Specialty Pharmaceuticals develops, manufactures, and commercializes life-saving antidotes used in hospitals and emergency care settings, including the clinically proven and leading products CroFab®, DigiFab®, and Voraxaze®.

Buy $800M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2025-08-05 Y-mAbs Therapeutics

Princeton, New Jersey, United States

Y-mAbs Therapeutics is a commercial-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. With a broad and advanced product pipeline, including pivotal-stage product candidates against a range of targets. Y-mAbs Therapeutics was founded in 2015 and is based in Princeton, New Jersey.

Buy $412M

Seller(S) 1

SELLER

Wellstat Therapeutics

Rockville, Maryland, United States
Category Company
Sector Life Science
DESCRIPTION

Wellstat Therapeutics is developer of an extensive and diverse pipeline of novel small molecule therapeutic agents. Wellstat Therapeutics is based in Rockville, Maryland.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
State: Maryland M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2023 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal